dr. rugo on rationale for the elaine study in esr1-mutated er /her2- breast cancer
Published 4 years ago • 215 plays • Length 1:26Download video MP4
Download video MP3
Similar videos
-
2:06
elaine 1: esr1 mutations in ctdna from er /her2- mbc treated with lasofoxifene or fulvestrant
-
1:47
dr. goncalves describes research involving the esr1 mutation in breast cancer
-
1:11
dr. rugo on the significance of the monarch i trial for breast cancer
-
1:12
dr. graff underscores unmet needs in esr1-mutated breast cancer
-
1:52
dr. rugo on swish trial for hr-positive breast cancer
-
2:35
lasofoxifene shows promise for women with esr1-mutated mbc
-
1:24
dr. rugo on extended adjuvant hormone therapy for breast cancer
-
2:32
dr. goetz on treatment challenges for esr1-mutant breast cancer
-
4:34
lasofoxifene vs fulvestrant for locally advanced/metastatic er /her2- breast cancer: elaine trial
-
1:29
dr. cristofanilli on lasofoxifene in esr1-mutant breast cancer
-
21:42
dr. hope rugo discusses capivasertib fda approval based on capitello-291 study
-
1:01
dr. graff on current treatments in esr1-mutant breast cancer
-
1:32
suzanne a. w. fuqua, phd, discusses the androgen receptor in breast cancer
-
1:57
elaine mardis on predictive markers for sensitivity to aromatase inhibitors in breast cancer
-
1:12
dr. fuqua on esr1 mutations in primary breast cancer
-
9:02
endocrine resistance in hr metastatic breast cancer
-
1:23
dr. rugo on pathway changes in breast cancer
-
6:55
mafalda oliveira, sabcs 2022: camizestrant vs fulvestrant for advanced er her2- breast cancer
-
0:41
dr. freedman discusses dual her2-targeted therapy in breast cancer